Tegavivint for advanced colorectal cancer after other treatments
Treatments studied
Part of Cancer, Digestive system, Genetic & congenital clinical trials.
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body (metastatic) and it is a common type called adenocarcinoma.
- You have already tried at least 2 different standard treatments (like specific chemotherapies and targeted therapies) and your cancer continued to grow or you could not tolerate them.
- You are 18 years or older, and your daily activities are not severely limited (ECOG 0 or 1).
- You are willing to have a small needle biopsy (tissue sample) taken before starting treatment and during the study.
- Your blood counts, liver, and kidney function must meet minimum levels (your doctor will check this).
- You do not have certain heart conditions, uncontrolled infections, or a history of severe allergic reactions to similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a new drug combination for people with a specific type of advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Carcinoma (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.